drugset

drugset / Trial / NCT05907330

Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis

NCT05907330 ↗

Phase 2 Unknown 45 enrolled Curacle Co., Ltd.

RandomizedParallel-groupTriple-blindTreatment

Summary

The study is designed to investigate efficacy and safety of CU104 in patients with moderate to severe ulcerative colitis.

Timeline

Start: 2024-06-01
Primary completion: 2026-02-28
Completion: 2026-03-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CU104	Unknown	100 mg	—

Indications